Genfit shares are trading higher after the company with its partner Ipsen said ELATIVE Phase 3 trial of elafibranor for primary biliary cholangitis met its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Genfit's shares are trading higher after the company and its partner Ipsen announced that the ELATIVE Phase 3 trial of elafibranor for primary biliary cholangitis met its primary endpoint.
June 30, 2023 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genfit's stock is trading higher due to positive results from the ELATIVE Phase 3 trial of elafibranor.
The positive results from the ELATIVE Phase 3 trial of elafibranor, a drug developed by Genfit in partnership with Ipsen, have led to an increase in Genfit's stock price. This is because successful clinical trials often lead to increased investor confidence and potential future revenues from the sale of the drug.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100